| D |
|
DABIGATRAN ETEXILATE IS EFFECTIVE AND SAFE FOR THE EXTENDED PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWING TOTAL HIP REPLACEMENT
|
| Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., v. Dijk N., Frosticks S.P., Hettiarachchi R., Hantel S., Schnee J., Büller H.R. |
| |
|
DABIGATRAN ETEXILATE VERSUS ENOXAPARIN IN PREVENTING VENOUS THROMBOEMBOLISM FOLLOWING TOTAL KNEE ARTHROPLASTY
|
| Friedman R.J., Caprini J.A., Comp P.C., Davidson B.L., Francis C.W., Ginsberg J., Huo M., Lieberman J., Muntz J.E., Raskob G.E., Clements M.L., Hantel S., Schnee J. |
| |
|
DAILY VITAMIN K SUPPLEMENTATION IMPROVES STABILITY OF TREATMENT WITH VITAMIN K ANTAGONISTS
|
| Rombouts E.K., Rosendaal F.R., van der Meer F.J.M. |
| |
|
DALTEPARIN SHORTENS HUMAN LABOR
|
| Hellgren M., Andersson E., Byström B., Edlund M., Holmberg A., Klimavicute A., Sennström M., Tzortzatos G., Malmström A., Ekman-Ordeberg G. |
| |
|
DALTEPARIN THROMBOPROPHYLAXIS IN CRITICALLY ILL PATIENTS WITH SEVERE RENAL INSUFFICIENCY: THE DIRECT STUDY
|
| Douketis J., Cook D., Zytaruk N., Heels-Ansdell D., Anderson D., Geerts W., Meade M., Guyatt G., Crowther M. |
| |
|
DAPSONE TREATMENT IN STEROID-DEPENDENT OR REFRACTORY ADULT ITP PATIENTS CAN AVOID IMMEDIATE SPLENECTOMY AFTER STEROID FAILURE
|
| Vancine-Califani S.M.C., De Paula E.V., Ozelo M.C., Orsi F.L.A., Fabri D.R., Annichino-Bizzacchi J.M. |
| |
|
DATABASE MANAGEMENT SYSTEM FOR A HAEMOPHILIA COMPREHENSIVE CARE CENTRE
|
| von Auer C., Rohlfing W., Scharrer I. |
| |
|
DATABASE ON RARE BLEEDING DISORDER (RBDS): PHENOTYPE AND GENOTYPE ANALYSIS ON 400 AFFECTED PATIENTS
|
| Spreafico M., Menegatti M., Garagiola I., Palla R., Tagliabue L., Karimi M., Lak M., Srivastava A., Saxena R., Shetty S., Kavakli K., Dolnicar M.B., Aronis-Vournas S., Asselta R., Duga S., Mannucci P.M., Peyvandi F. |
| |
|
DDAVP VERSUS VWF-CONTAINING FACTOR CONCENTRATE IN A PATIENT WITH ACQUIRED VON WILLEBRAND SYNDROME (AVWS) ASSOCIATED WITH ESSENTIAL THROMBOCYTHEMIA (ET)
|
| Kruse-Jarres R. |
| |
|
D-DIMER AND PROGNOSIS IN PATIENTS WITH CHRONIC ATRIAL FIBRILLATION
|
| Mahé I., Drouet L., Chassany O., Bal dit Sollier C., Aumont M., Beaufils P., Simoneau G., Bergmann J. |
| |
|
D-DIMER AS AN ADJUNCT TO COMPRESSION ULTRASONOGRAPHY IN PATIENTS WITH SUSPECTED RECURRENT IPSILATERAL DEEP VEIN THROMBOSIS. A PROSPECTIVE COHORT STUDY
|
| Prandoni P., Tormene D., Dalla Valle F., Concolato A., Pesavento R., Pagnan A. |
| |
|
D-DIMER AS PREDICTIVE FACTOR FOR VENOUS THROMBOEMBOLISM IN CANCER PATIENTS BEFORE CHEMOTHERAPY
|
| Carpenedo M., Arpaia G., Verga M., Mastrogiacomo O., Fagnani D., Milani M., Cimminiello C. |
| |
|
D-DIMER IN PATIENTS WITH ACUTE LEUKEMIA AFTER TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS
|
| Atamonov V.A., Vavilova T.V., Fregatova L.M., Zubarovskaya L.S., Semenova E.V., Bondarenco S.N. |
| |
|
D-DIMER IN PATIENTS WITH CLINICAL SIGNS OF ATHEROTHROMBOSIS IN DIFFERENT VASCULAR BEDS
|
| Fedotkina J., Komarov A., Egorova E., Ryabysh E., Vitsenya M., Titaeva E., Staroverov I., Panchenko E., Dobrovolsky A. |
| |
|
D-DIMER LEVELS CORRELATE WITH MORTALITY IN PATIENTS WITH ACUTE PULMONARY EMBOLISM: FINDINGS FROM THE RIETE REGISTRY
|
| Grau E., Tenias J., Soto M., Gutierrez M., Lecumberri R., Perez J., Tiberio G. |
| |
|
D-DIMER LEVELS IN RELATION TO FACTOR V 1691 GENOTYPE AND ORAL ANTICOAGULATION. A CASE-CONTROL-STUDY OF 46 HOMOZYGOUS AND HETEROZYGOUS FACTOR V LEIDEN PATIENTS
|
| Harbrecht U., Gnida C., Oldenburg J. |
| |
|
D-DIMER LEVELS IN RELATION TO FACTOR V 1691 GENOTYPE AND ORAL ANTICOAGULATION. A CASE-CONTROL-STUDY OF 46 HOMOZYGOUS AND HETEROZYGOUS FACTOR V LEIDEN PATIENTS
|
| Harbrecht U., Gnida C., Oldenburg J. |
| |
|
D-DIMER MEASUREMENT AND THROMBOPHILIA SCREENING IN THE FOLLOW-UP OF PATIENTS WITH A HISTORY OF VENOUS THROMBOEMBOLISM
|
| Ombandza E., Samama M., Conard J., Horellou M., Elalamy I. |
| |
|
D-DIMER REPORTING: WHAT'S THE PROBLEM FOR THE ELECTRONIC HEALTH RECORD? AN ONTARIO PERSPECTIVE
|
| Raby A., Crowther M., Flynn G. |
| |
|
D-DIMER TESTING AND RECURRENT VENOUS THROMBOEMBOLISM AFTER UNPROVOKED PULMONARY EMBOLISM
|
| Pengo V., Cosmi B., Legnani C., Marzot F., Tosetto A., Testa S., Ghirarduzzi A., Palareti G. |
| |
|
D-DIMER VALUE AND ECHOCARDIOGRAPHIC CHANGES AS PREDICTORS OF THROMBOEMBOLIC COMPLICATIONS AFTER THE FONTAN OPERATION
|
| Hendler M.F., Alberto F., Meschengieser S.S., Conejeros W.M., Roman M.I., Sanchez-Luceros A., Casais P., Schlichter A., Kreutzer G.O., Lazzari M.A. |
| |
|
D-DIMER WHILE ON ORAL ANTICOAGULANTS (OAC) IS ASSOCIATED WITH SUBSEQUENT RECURRENT VENOUSTHROMBOEMBOLISM OFF OF OAC IN WOMEN BUT NOT MEN
|
| Rodger M.A., Kovacs M.J. |
| |
|
DE NOVO ATOMIC FORCE MICROSCOPY OF INTRACORONARY THROMBUS: NEW INSIGHTS INTO FIBRIN CLOT ARCHITECTURE AND IMPLICATIONS FOR FIBRINOLYSIS
|
| Lim B.B., Prasad A., Rihal C., Jahangir A. |
| |
|
DECLINING RATE OF VENOUS THROMBOEMBOLISM IN PATIENTS EVALUATED FOR PULMONARY EMBOLISM IN TWO UNITED STATES EMERGENCY DEPARTMENTS AND LOW RATE OF EMPIRIC ANTICOAGULATION
|
| Nordenholz K.E., Mitchell A.M., Kline J.A. |
| |
|
DECREASE FACTOR VIIA/ANTITHROMBIN COMPLEXES IN 31 SUBJECTS BELONGING TO 7 FAMILIES WITH FVII DEFICIENCY
|
| Spiezia L., Rossetto V., Gavasso S., Tognin G., Morboeuf O., Woodhams B., Simioni P. |
| |
|
DECREASE FACTOR VIIA/ANTITHROMBIN COMPLEXES IN PATIENTS WITH VENOUS THROMBOEMBOLISM: A NEW INSIGHT IN THE PATHOGENETIC MECHANISM
|
| Spiezia L., Rossetto V., Gavasso S., Tognin G., Morboeuf O., Woodhams B., Adam M., Simioni P. |
| |
|
DECREASE OF SOLUBLE P-SELECTIN AND INHIBITION BOTH, ACTIVATED FACTOR XA AND THROMBIN AFTER I.V.ENOXAPARIN DURING PCI
|
| Kvasnicka J., Horak J., Malikova I., Kvasnicka T., Necasova Z. |
| |
|
DECREASED ADAMTS13 AND ANTI-ADAMTS13 IN THE ANTIPHOSPHOLIPID SYNDROME (APS)
|
| Austin S.K., Starke R.D., Lawrie A., Cohen H., Machin S.J., Mackie I.J. |
| |
|
DECREASED ADAMTS-13 IS ASSOCIATED WITH A POOR PROGNOSIS IN SEPSIS-INDUCED ORGAN FAILURE
|
| Martin K., Borgel D., Lerolle N., Feys H.B., Trinquart L., Vanhoorelbeke K., Deckmyn H., Legendre P., Diehl J., Baruch D. |
| |
|
DEEP VEIN THROMBOSIS AND THE RISK OF RECURRENT PULMONARY EMBOLISM
|
| Jimenez D., Díaz G., Vidal R., Marin E., Aracil E., Sueiro A., Yusen R.D. |
| |
|
DEEP VENOUS THROMBOSIS IN THE ANTENATAL PERIOD IN A LARGE COHORT OF PREGNANCIES FROM WESTERN INDIA
|
| Ghosh K., Vora S., Shetty S. |
| |
|
DEFIBROTIDE AND ITS MOLECULAR FRACTIONS DO NOT CROSS-REACT WITH HIT ANTIBODIES. IMPLICATIONS IN THE MANAGEMENT OF HIT
|
| Fareed J., Hoppensteadt D., Cella G., Messmore H.L., Iacobelli M., Jeske W., Walenga J.M. |
| |
|
DEFIBROTIDE DIRECTLY ENHANCE THE ACTIVITY OF PLASMIN
|
| Echart C., Repice C., Ferro L., Iacobelli M. |
| |
|
DEFIBROTIDE MEDIATED INHIBITION OF HEPARINASE I. POTENTIAL CLINICAL IMPLICATIONS
|
| Fareed J., Sonevytsky A., Iqbal O., Jeske W.P., Iacobelli M., Hoppensteadt D. |
| |
|
DEFIBROTIDE MODULATES HEPARANASE EXPRESSION IN ENDOTHELIAL AND TUMOR CELLS: A POTENTIAL MECHANISM OF ACTION
|
| Echart C., Distaso M., Kumar V., Ferro L., Iacobelli M. |
| |
|
DEFIBROTIDE PROTECTS ENDOTHELIAL CELLS AGAINST STRESS-INDUCED CELL DEATH VIA INHIBITION OF THE EXTRINSIC APOPTOSIS PATHWAY
|
| Echart C., Iacobelli M., Ignoni T., Ferro L., Eissner G. |
| |
|
DEFICIENCY OF PLASMINOGEN ACTIVATOR INHIBITOR-2 IMPAIRS NUTRITIONALLY INDUCED MURINE ADIPOSE TISSUE DEVELOPMENT
|
| Lijnen R.H., Van Hoef B., Scroyen I. |
| |
|
DEFICIENCY OF SRC HOMOLOGY 2 DOMAIN-CONTAINING INOSITOL 5-PHOSPHATASE 1 (SHIP1) AFFECTS PLATELET RESPONSES AND THROMBUS GROWTH
|
| Gratacap M.P., Severin S., Lenain N., Alvarez L., Hollande E., Penninger J., Gachet C., Plantavid M., Payrastre B. |
| |
|
DEFINING BENEFIT-RISK TRADEOFF VALUES FOR VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS AFTER ORTHOPEDIC SURGERY (OS)
|
| Lazo-Langner A., Coyle D.A., Wells P.S., Scarvelis D., Forgie M.A., Rodger M.A. |
| |
|
DEFINING THE STRUCTURE OF MEMBRANE-BOUND HUMAN BLOOD COAGULATION FACTOR VA
|
| Stoilova-McPhie S., Awosile F.S., Parmenter C.D.J., Segers K., Villoutreix B.O., Nicolaes G.A.F. |
| |
|
DEFINITIVE PACEMAKER'S IN ANTICOAGULATED PATIENTS
|
| Quintana M., Sánchez M., Taberna M., Simón A.A., Gonzalez A. |
| |
|
DEHYDROEPIANDROSTERONE INHIBITS PLATELET AGGREGATION
|
| Sarasso C., Baldassarri S., Zanfa M., Bertoni A., Sinigaglia F. |
| |
|
DELAY IN STARTING ORAL ANTICOAGULATION IN PATIENTS WITH ACUTE VENOUS THROMBOEMBOLISM (VTE): ANALYSIS FROM THE MASTER REGISTRY
|
| Moia M., Agnelli G., Ageno W., Palareti G., Imberti D., Pistelli R., Rossi R., Verso M. |
| |
|
DELAYED HYPERSENSITIY TO LOW MOLECULAR WEIGHT HEPARIN (LMWH) IN PREGNANCY
|
| Jacobson B.F., Schapkaitz E. |
| |
|
DELAYED ONSET OF LOW MOLECULAR WEIGHT HEPARIN INDUCED THROMBOCYTOPENIA TYPE II IN A CARDIAC PATIENT
|
| Oliveira S.C., Quarentei R., Souza F., Cavalheiro-Filho C., Rached R., Lisboa L., Oliveira S., Bydlowski S. |
| |
|
DENDROASPIN, AN RGD-CONTAINING SNAKE VENOM PROTEIN INITIATES ACTIVATION OF CYTOSOLIC PHOSPHOLIPASE A2-ALPHA ACTIVATION
|
| Xia M., Lu D., Scully M., Lu X., Kakkar V. |
| |
|
DENGUE FEVER AND THROMBOCYTOPENIA: A DEADLY DUO
|
| Lale A., Lale S., Bick R., Fareed J. |
| |
|
DESIGN AND IN VITRO CHARACTERIZATION OF A PHOTODYNAMIC ANTICOAGULANT
|
| Müller J., Heckel A., Buff M., Raddatz M., Pötzsch B., Mayer G. |
| |
|
DESIGN OF A PLATELET SUBSTITUTE UTILISING HOST FIBRINOGEN TO ENHANCE HAEMOSTASIS
|
| Appleby J.A., Walker G.F., Middleton S.M., Goodall A.H. |
| |
|
DESMOPRESSIN IN PATIENTS WITH CONGENITAL DISORDERS OF PRIMARY HAEMOSTASIS: FOUR YEAR PROSPECTIVE EVALUATION
|
| Coppola A., Cimino E., Amoriello A., Tufano A., De Simone C., Macarone Palmieri N., Coppola D., Cirillo F., Cerbone A.M., Di Minno G. |
| |
|
DESMOTEPLASE-MEDIATED PLASMINOGEN ACTIVATION AND CLOT LYSIS ARE ANTAGONIZED BY THE LYSINE ANALOGUE TRANEXAMIC ACID
|
| Niego B., Horvath A., Coughlin P.B., Pugsley M.K., Medcalf R.L. |
| |
|
DETECTING PROTHROMBOTIC STATES USING A THROMBIN GENERATION TEST IN RELATIVES OF PATIENTS WITH VENOUS THROMBOEMBOLISM AND FACTOR V LEIDEN
|
| Couturaud F., Duchemin J., Abgrall J., Leroyer C., Mottier D. |
| |
|
DETECTION OF 23 NOVEL MUTATIONS IN LEBANESE HEMOPHILIA PATIENTS
|
| Djambas Khayat C., Salem N., Chouery E., Corbani S., Moix I., Nicolas E., Morris M.A., de Moerloose P., Megarbane A. |
| |
|
DETECTION OF ANTI-BETA2-GLYCOPROTEIN I ANTIBODIES: THE INFLUENCE OF DIFFERENT ANTIGEN PREPARATIONS
|
| Cavazzana A., Pengo V., Tonello M., Noventa F., Borghi M.O., Grossi C., Meroni P.L., Reber G., Ruffatti A. |
| |
|
DETECTION OF ANTI-HAEMOSTATIC EFFECT OF PLASMA DILUTION VIA THROMBIN GENERATION
|
| Schols S.E.M., van der Meijden P.E.J., Curvers J., Heemskerk J.W.M., van Pampus E.C.M. |
| |
|
DETECTION OF FUNCTIONAL FACTOR VII INHIBITORS IN PLASMA
|
| Christiansen K., Norengaard L., Ingerslev J. |
| |
|
DETECTION OF HYPERCOAGULABILITY IN HIP ARTHROPLASTY PATIENTS BY REPEATED MEASSUREMENTS OF URINE PROTHROMBIN FRAGMENT 1.2
|
| Ryge C., Rud Lassen M., Borris L., Breindal M. |
| |
|
DETECTION OF HYPERCOAGULABILITY IN PATIENTS WITH THYROID CANCER
|
| Van Dreden P., Rousseau A., Fontaine S., Exner T., Woodhams B.J. |
| |
|
DETECTION OF LARGE DELETIONS IN HAEMOPHILIA A: CARRIER DETECTION BY MP/LC (MULTIPLEX PCR/LIQUID CHROMATOGRAPHY)
|
| Vinciguerra C., Force A., Pellecchia D., Fretigny M., Negrier C. |
| |
|
Detection of nonmuscle myosin-IIA, inclusions in neutrophils, D-variant of fibulin-1 and mutations within MYH9 gene in patients with MYH9-ralated disorders
|
| Rittich S., Mikulenkova D., Salaj P., Hrachovinova I. |
| |
|
DETECTION OF PARTIAL F8 GENE DELETIONS IN HAEMOPHILIA A CARRIER DIAGNOSIS
|
| Keeney S., Neville-Rutherford C., Bolton-Maggs P., Hay C., Cumming A. |
| |
|
DETERMINANTS OF PLATELET ACTIVATION IN HEART FAILURE
|
| Santilli F., Basili S., Lattanzio S., Cavoni A., Guizzardi G., De Feudis L., Traisci G., Ciabattoni G., Davì G., Patrono C. |
| |
|
DETERMINANTS OF PLATELET AGGREGATE FORMATION WITH EITHER POLYMORPHONUCLEAR LEUKOCYTES OR MONOCYTES IN HUMAN WHOLE BLOOD
|
| Pampuch A., Izzi B., Costanzo S., Vohnout B., Iacoviello L., Donati M., Cerletti C., de Gaetano G. |
| |
|
DETERMINANTS OF THE ENDOGENOUS THROMBIN POTENTIAL IN A DUTCH THROMBOPHILIC FAMILY
|
| Wichers I.M., Tanck M.W.T., Meijers J.C.M., Reitsma P.H., Buller H.R., Middeldorp S. |
| |
|
DETERMINATION OF ANTI-ADAMTS13 AUTOANTIBODIES IN THROMBOTIC TROMBOCITOPENIC PURPURA (TTP) PATIENTS: COMPARISON OF TWO DIFFERENT METHODS
|
| Palla R., Valsecchi C., Bajetta M.T., Canciani M.T., Lavoretano S., Mannucci P.M., Peyvandi F. |
| |
|
DETERMINATION OF CLOPIDOGREL MAIN METABOLITE IN PLASMA USEFUL TOOL FOR THERAPY MONITORING ?
|
| Mani H., Toennes S.W., Linnemann B., Schwonberg J., Kauert G.F., Lindhoff-Last E. |
| |
|
DETERMINATION OF PLASMA COAGULATION FACTOR XIII WITH THE NOVEL FLUOROGENIC ISOPEPTIDASE ASSAY
|
| Oertel K., Hunfeld A., Specker E., Reiff C., Seitz R., Pasternack R., Dodt J. |
| |
|
DETERMINATION OF PROTEIN C LEVEL IN NEONATES WITH SEPSIS LIKE ILLNESS
|
| Karimi M., Pishva N., Shahbazi M., Afrasiabi A., Jamalian N. |
| |
|
DETERMINATION OF THE ANTICOAGULANT ACTIVITY OF IDRAPARINUX IN PATIENTS BY PROTHROMBIN-INDUCED CLOTTING TIME AND HEPTEST
|
| Harenberg J., Giese C., Hagedorn A., Träger I. |
| |
|
DETERMINATION OF THE INTEGRIN BINDING PROPERTIES OF THE PUTATIVE INTEGRIN-BINDING MOTIFS OF ADAM PROTEINS USING MUTANTS BASED UPON A DENDROASPIN SCAFFOLD
|
| Lu X., Xia M., Lu D., Scully M., Kakkar V. |
| |
|
DETERMINATION OF THE OESTROGEN RESPONSIVENESS OF A POLYMORPHIC ELEMENT IN THE HUMAN FACTOR IX GENE PROMOTER
|
| Adams B., Winship P.R. |
| |
|
DETERMINATION OF THROMBIN-ALPHA2MACROGLOBULIN COMPLEXES BY A NEW IMMUNO-ACTIVITY ASSAY
|
| Berry L.R., Parmar N., Chan A.K.C. |
| |
|
DETERMINATION OF TISSUE FACTOR ORIGIN USING SIRNA KNOCKDOWN APPROACH IN HUMAN PERIPHERAL BLOOD WHITE CELLS
|
| Sovershaev M., Egorina E., Devold H., Olsen J., Østerud B. |
| |
|
DETERMINATION OF VKORC1 AND CYP2C9 GENOTYPES IS OF LIMITED VALUE DURING CHRONIC ANTICOAGULATION WITH ACENOCOUMAROL
|
| Lambert C., Gala J., Dessomme B., Deneys V., Hermans C. |
| |
|
DEVELOPING ANTIDOTE CONTROLLED ANTIPLATELET THERAPIES BY TARGETING THE VWF - GP IB-IX-V INTERACTION
|
| Oney S., Layzer J., Nimjee S.M., Que N.S., Ginsburg D., Lopez J.A., Arepally G.M., Becker R.C., Sullenger B.A. |
| |
|
DEVELOPMENT AND VALIDATION OF A MULTIPLEXED FLUORESCENT BEAD-BASED IMMUNOASSAY FOR SIMULTANEOUS QUANTIFICATION OF COAGULATION AND FIBRINOLYSIS PARAMETERS IN HUMAN PLASMA
|
| Cung T., Amiral J., Haeberli A. |
| |
|
DEVELOPMENT AND VALIDATION OF A PREDICTIVE MODEL FOR CHEMOTHERAPY-ASSOCIATED THROMBOSIS
|
| Khorana A.A., Kuderer N.M., Culakova E., Lyman G.H., Francis C.W. |
| |
|
DEVELOPMENT OF A NOVEL ONE STEP LATERAL FLOW DEVISE FOR QUALITATIVE DETECTION OF PROTHROMBIN FRAGMENT F1+2 IN URINE
|
| Ryge C., Lassen M., Borris L., Breindahl M., Newton M. |
| |
|
DEVELOPMENT OF A SPECIALISATION PROGRAM FOR HAEMOPHILIA NURSES IN ITALY (SPHINX)
|
| v. Mackensen S. |
| |
|
DEVELOPMENT OF LONG-ACTING FVIIA DERIVATIVES BY GLYCOPEGYLATION
|
| Bayer R.J., Ostergaard H., Kalo M.S., Holm P.K., Kinealy K., Sørensen B.B., Bjørn S.E., Zopf D., Stennicke H.R. |
| |
|
DEVELOPMENT OF MEGAKARYOCYTE-SPECIFIC LENTIVIRAL VECTORS FOR GENE THERAPY OF PLATELET DISORDERS
|
| De Waele L., Freson K., Gillijns V., Thys C., Van Geet C., Collen D., VandenDriessche T., Chuah M. |
| |
|
DEVELOPMENT OF MONOCLONAL ANTIBODIES FOR DIRECT DETECTION OF FACTOR XIII ACTIVATION PEPTIDE IN PLASMA
|
| Schroeder V., Kohler H.P. |
| |
|
DEXTROMETHORPHAN REDUCES ATHEROSCLEROSIS AND NEOINTIMA FORMATION IN MICE
|
| Shi G., Liu S., Wu H. |
| |
|
DIAGNOSIS AND FOLLOW UP OF FACTOR XIII DEFICIENCY: COMPARISON OF DIFFERENT CLOT-SOLUBILITY TESTS
|
| Blanco A.N., Grosso S.H., Bastos L.A., Meschengieser S.S., Lazzari M.A. |
| |
|
DIAGNOSIS AND THERAPY OF CHILDREN WITH INHERITED DEFECTS OF PLATELET FUNCTION IN GERMAN SPEAKING COUNTRIES: QUALITY PROJECT THROMKID
|
| Streif W., Streif W., Olivieri M., Weickardt S., Rott H., Nowak- Göttl U., Wermes C., Escuriola C., Laws H., Harbrecht U., Schneppenheim R., Eberl W., Knöfler R. |
| |
|
DIAGNOSIS OF THE ANTIPHOSPHOLIPID SYNDROME BY CALIBRATED AUTOMATED THROMBINOGRAPHY
|
| Devreese K.M.J., Hoylaerts M.F. |
| |
|
DIAGNOSTIC ACCURACY OF THE TRIAGE D-DIMER TEST FOR EXCLUSION OF VENOUS THROMBOEMBOLISM IN OUTPATIENTS
|
| Ghys T., Verschraegen I., Achtergael W., Leus B., Jochmans K. |
| |
|
DIAGNOSTIC EFFICACY OF SYSTEMATIC INVESTIGATION OF NON-VON WILLEBRAND BLEEDERS: RESULTS OF A PROSPECTIVE STUDY
|
| Rapson D., Bowman M., Lillicrap D., James P. |
| |
|
DIAGNOSTIC SIGNIFICANCE OF TESTING ANTI-BETA2-GLYCOPROTEIN I ANTIBODIES FOR THE ANTIPHOSPHOLIPID SYNDROME
|
| Kato M., Atsumi T., Sakai Y., Amengual O., Bohgaki T., Kataoka H., Horita T., Yasuda S., Koike T. |
| |
|
DIAGNOSTIC WORK-UP AND DIAGNOSTIC SAFETY IN PATIENTS WITH SUSPECTED DEEP VEIN THROMBOSIS DATA FROM THE GERMAN TULIPA REGISTRY
|
| Schellong S.M., Gerlach H., Hach-Wunderle V., Rabe E., Riess H.B., Carnarius H., Eberle S., Bauersachs R. |
| |
|
DIAMOND PARTICLES OF MICROMETRIC SIZE ARE INTERNALIZED BY ENDOTHELIAL CELLS
|
| Pawlowska Z., Okroj W., Jerczynska H., Kaminska M., Komorowski P., Walkowiak B. |
| |
|
DIET MANIPULATION OF ATHEROSCLEROTIC LESIONS IN THE FHD PIG MODEL
|
| Bal dit Sollier C., Bonneau M., Kang C., Berge N., Brouland J., Baudin B., Drouet L. |
| |
|
DIETARY EFFECT ON VITAMIN K-DEPENDED COAGULATION FACTORS AND ON PLATELETS' AGGREGATION
|
| Makri L.P., Makris M.P., Papamichos S.I., Makris P.E. |
| |
|
DIFFERENCES BETWEEN FIBRINOGEN BINDING AND RECEPTOR ACTIVATION MEASURED BY FLOW CYTOMETRY INDICATE THE EXISTENCE OF A TRANSITION STATE IN GPIIB/IIIA, RECOGNISED BY PAC-1 BUT NOT BINDING FIBRINOGEN
|
| Vretenbrant Öberg K., Ramström S., Lindahl T.L. |
| |
|
DIFFERENCES IN ENDOTHELIAL CELL ACTIVATION BY IGG FROM PATIENTS WITH THE ANTIPHOSPHOLIPID SYNDROME OR WITH IMMUNE THROMBOCYTOPENIC PURPURA
|
| Dunoyer-Geindre S., Boehlen F., Reber G., Satta N., Kruithof E.K.O., de Moerloose P. |
| |
|
DIFFERENCES IN PLATELET RESPONSE TO ADP AND CRP ARE CORRELATED WITH VARIATION IN THE RESTING PLATELET TRANSCRIPTOME
|
| Burns P., Gusnanto A., Ellis P., Angenent W., Dudbridge F.P., Dunn R., Farndale R.W., Garner S.F., Jones C.I., Langford C.F., Rice C.M., Walton J., Ouwehand W.H., Goodall A.H., Watkins N.A. |
| |
|
DIFFERENCES IN THE OLIGOSACCHARIDE COMPOSITION OF GENERIC VERSIONS OF ENOXAPARIN AND DALTEPARIN
|
| Jeske W.P., Brubaker A., Hoppensteadt D., Walenga J.M., Ma Q., Fareed J. |
| |
|
DIFFERENCES IN THROMBOPHILIA ASSAY RESULTS BETWEEN COMMERCIAL REFERENCE PLASMAS USING THE SSC/ISTH SECONDARY COAGULATION STANDARD LOT#3 IN UK NEQAS FOR BLOOD COAGULATION PROFICIENCY TESTING EXERCISES
|
| Woods T.A., Jennings I., Kitchen S., Kitchen D.P., Walker I.D. |
| |
|
DIFFERENT CUT-OFF VALUES OF THREE D-DIMER (DD) TESTS TO ESTABLISH DURATION OF ORAL ANTICOAGULATION TREATMENT (OAT) AFTER A VENOUS THROMBOEMBOLISM (VTE)
|
| Legnani C., Cosmi B., Cini M., Mattarozzi S., Tripodi A., Tosetto A., Palareti G. |
| |
|
DIFFERENT INTEGRINS, DIFFERENT STATES, DIFFERENT SHAPES?
|
| Rocco M., Rosano C., Weisel J.W., Horita D.A., Hantgan R.R. |
| |
|
DIFFERENT PATTERN OF TF EXPRESSION IN PLATELETS, LEUKOCYTES AND AGGREGATES OF CAD PATIENTS
|
| Brambilla M., Colnago D., Demetrio M., Marenzi G., Gertow K., Tremoli E., Camera M. |
| |
|
DIFFERENTIAL ACTIVATION OF PROTHROMBIN BY FACTOR XA, TAIPAN VENOM AND ECARIN. PHARMACOLOGIC IMPLICATIONS
|
| Maddineni J., Florian M., Jeske W.P., Bick R., Fareed J. |
| |
|
DIFFERENTIAL ANALYSIS BY 2-DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS (2D-DIGE) OF HUMAN PLATELET PROTEINS RELEASED FOLLOWING THROMBIN ACTIVATION: IDENTIFICATION OF LAMIN A, A NOVEL PLATELET PROTEIN
|
| Della Corte A., Maugeri N., Pampuch A., Cerletti C., de Gaetano G., Rotilio D. |
| |
|
DIFFERENTIAL DETECTION OF WILD-TYPE AND MUTANT MYH9 MRNA AND NMMHC-IIA POLYPEPTIDE REVEALS DOMINANT-NEGATIVE EFFECT IN GRANULOCYTES AND HAPLOINSUFFICIENCY IN PLATELETS IN PATIENTS WITH MYH9 DISORDERS
|
| Kunishima S., Matsushita T., Kojima T., Okada H., Yamazaki T., Hamaguchi M., Saito H. |
| |
|
DIFFERENTIAL DOSING OF ENOXAPARIN (ENOX) IN TERM AND PRETERM NEONATES
|
| Malowany J.I., Knoppert D.C., Lee D.S., Wu J., McCusker P., Massicotte P., Williams S., Chan A.K.C. |
| |
|
DIFFERENTIAL EFFECTS OF ANTI-PLATELET DRUGS ON THROMBUS FORMATION AND THROMBUS STABILITY
|
| Stephens G., Gao D., Phillips D.R., Andre P. |
| |
|
DIFFERENTIAL EFFECTS OF CONVENTIONAL AND LOW DOSE ORAL HORMONE THERAPY, TIBOLONE AND RALOXIFENE ON FUNCTIONALITY OF THE ACTIVATED PROTEIN C SYSTEM
|
| Eilertsen A.L., Liestøl S., Mowinckel M., Hemker H.C., Sandset P. |
| |
|
DIFFERENTIAL EFFECTS OF CONVENTIONAL DOSE HORMONE THERAPY, LOW DOSE HT, TIBOLONE AND RALOXIFENE ON C-REACTIVE PROTEIN AND OTHER INFLAMMATORY MARKERS
|
| Eilertsen A.L., Sandvik L., Steinsvik B., Sandset P. |
| |
|
DIFFERENTIAL EFFECTS OF FXA INHIBITORS AND HEPARINS IN SIMULATED ARTERIAL AND VENOUS THROMBOSIS
|
| Walenga J.M., Jeske W.P., Prechel M., Swank J., Hoppensteadt D., Iqbal O., Cunanan J., McGeehan E., Bakhos M. |
| |
|
DIFFERENTIAL EFFECTS OF RETINOIDS ON THE PROCOAGULANT ACTIVITY (PCA) AND CYTO-DIFFERENTIATION OF LEUKEMIC CELLS FRESHLY ISOLATED FROM ACUTE PROMYELOCYTIC LEUKEMIA (APL) PATIENTS
|
| Balducci D., Marchetti M., Russo L., Vignoli A., Falanga A. |
| |
|
DIFFERENTIAL EFFECTS OF TRANSDERMAL AND ORAL ESTRADIOL/NORETHISTERONE ACETATE HORMONE THERAPIES ON COAGULATION AND FIBRINOLYTIC MARKERS
|
| Brosnan J.F., Sheppard B.L., Norris L.A. |
| |
|
DIFFERENTIAL EXPRESSION OF TF IN CARDIAC HYPERTROPHY AND ITS INVOLVEMENT IN THE PROGRESSION OF THE DISEASE
|
| Frentzou A., Collier M.E.W., Li C., Seymour A.L., Ettelaie C. |
| |
|
DIFFERENTIAL VENOUS THROMBOEMBOLISM PROPHYLAXIS PRESCRIPTION IN PATIENTS WITH SURGICAL AND NON-SURGICAL CONDITIONS ADMITTED TO SURGICAL UNITS
|
| Gibbs H., Collins R., Gibbs J. |
| |
|
DIFFERENTIATION OF CD34+ CELLS MEDIATED BY THROMBOPOIETIN AND MONOCYTES/MACROPHAGES
|
| D'Atri L.P., Negrotto S., Pozner R.G., Pacienza N., Landoni V.I., Gomez R.M., Torres O., Isturiz M., Schattner M. |
| |
|
DIFFERENTIATION OF LOW MOLECULAR WEIGHT HEPARINS AS STUDIED BY MOLECULAR WEIGHT PROFILE AND HEPARINASE-I DEPOLYMERIZATION: PHARMACOLOGIC IMPLICATIONS
|
| Brubaker A., Jeske W.P., Hoppensteadt D., Maddineni J., Kujawski M., Fareed J. |
| |
|
DIFFICULTIES IN THE TREATMENT OF REFRACTORY IMMUNE THROMBOCYTOPENIC PURPURA WITH BLEEDING SYMPTOMS
|
| Serpa M.G., Okazaki E., Zeinad A.K., Villaça P.R., Bassitt R.P., Chamone D.F., D'Amico E.A. |
| |
|
DIMERIC 2-GPI BINDS TO LDL-BINDING DOMAIN 1 OF APOER2. PLATELETS EXPRESS THREE 3 DIFFERENT SPLICE VARIANTS OF APOER2 OF WHICH APOER24-5 IS THE MOST ABUNDANT
|
| Urbanus R.T., Pennings M.T.T., Tekelenburg W., Lenting P.J., Derksen R.H.W.M., de Groot P.G. |
| |
|
DIRECT EVIDENCE OF SPECIFIC INTERACTIONS OF FIBRINOGEN ALPHA C REGIONS WITH THE CENTRAL E REGION AND WITH EACH OTHER
|
| Litvinov R.I., Tsurupa G., Yakovlev S., Medved L., Weisel J.W. |
| |
|
DIRECT PROTECTIVE EFFECT OF ACTIVATED PROTEIN C ON MAST CELLS DEGRANULATION
|
| Makarova A., Gorbacheva L., Zamolodchikova T., Rumsh L., Smirnov M., Strukova S. |
| |
|
DIRECT THROMBUS IMAGING WITH MAGNETIC RESONANCE IN THE DISCRIMINATION BETWEEN ACUTE AND CHRONIC DEEP VEIN THROMBOSIS; A PROSPECTIVE PROOF-OF-PRINCIPLE STUDY
|
| van Rooden C.J., Westerbeek R.E., Kok S.W., van Gils A.P.G., de Roos A., Huisman M.V. |
| |
|
DISCORDANT ANTIBODY RESPONSE IN MONOZYGOTIC TWINS WITH SEVERE HAEMOPHILIA A
|
| ter Avest P.C., Gouw S.C., van Helden P.M., Voorberg J., van den Berg H.M. |
| |
|
DISCOVERY AND CHARACTERIZATION OF A POTENT NEUTRALIZING ANTI-VWF A1 DOMAIN SPECIFIC APTAMER
|
| Lagasse H.A.D., Merlino P.G., Marsh H.N., Makim A., Lewis S.D., Diener J.L. |
| |
|
DISCOVERY OF A POTENT, DIRECT THROMBIN INHIBITING APTAMER
|
| Wagner-Whyte J., Khuri S.F., Preiss J.R., Kurz J.C., Olson K., Hatala P., Boomer R.M., Fraone J.M., Brosnan N., Makim A., Lewis S.D., Cai L., McCauley T., Hutabarat R., Horvath C., Funk W.D., Deitcher S.R., Thatte H., Hussaini B., Treanor P., Rottman J.B., Diener J.L. |
| |
|
DISCOVERY OF COMPOUNDS THAT INHIBIT FACTOR VA-MEMBRANE INTERACTION BY IN SILICO SCREENING
|
| Segers K., Sperandio O., Sack M., Fischer R., Miteva M.M., Rosing J., Nicolaes G.A.F., Villoutreix B.O. |
| |
|
DISINTEGRIN SUPPRESSES HUMAN VASCULAR ENDOTHELIAL CELL MIGRATION AND INVASION BY REGULATING PLATELET ACTIVATION
|
| Jang Y., Jeon O., Kim D., Choi W., Rhee J., Kim D. |
| |
|
DISORDERS OF COLLAGEN-INDUCED AGGREGATION OF PLATELETS FROM CATTLE AND RATS WITH CHEDIAK-HIGASHI SYNDROME
|
| Ito K., Ohnishi K., Hashino S., Ikeda M. |
| |
|
DISRUPTION OF PAI-1 CIRCADIAN RHYTHM IN OBESE SUBJECTS MAY EXPLAIN A CHANGE IN THE TIME OF ONSET OF MYOCARDIAL INFARCTION
|
| Dadoun F., Achard V., Paganelli F., Rey M., Bellan A., Becquet D., Alessi M., Juhan-Vague I., Dutour A. |
| |
|
DISSECTION OF STRUCTURAL REQUIREMENTS FOR ACTIVATED PROTEIN C ANTICOAGULANT VERSUS CYTOPROTECTIVE ACTIVITIES
|
| Mosnier L.O., Yang X.V., Griffin J.H. |
| |
|
DISTAL DVT: WORTH DIAGNOSING? YES
|
| Schellong S.M. |
| |
|
DISTINCT EFFECTS OF CYCLO-OXYGENASE (COX)-1 INHIBITOR OF ASPIRIN AND P2Y12 INHIBITOR OF CLOPIDOGREL ON THE THREE DIMENSIONAL GROWTH OF ARTERIAL THROMBI FORMED AT SITE OF FUNCTIONAL DAMAGE OF ENDOTHELIAL BY FECL3
|
| Kawamura Y., Ishida H., Takahari Y., Goto S. |
| |
|
DISTINCTIVE THROMBOELASTOGRAPHIC FINDINGS (TEG-PM IN RESPONSE TO ADP) IN A FAMILY WITH BERNARD SOULIER SYNDROME
|
| Güthner C., Clemetson J., Clemetson K., Brand B., Asmis L. |
| |
|
DNA REPAIR GENE XRCC1 AND XPD POLYMORPHISMS AND THEIR ASSOCIATION WITH CORONARY ARTERY DISEASE RISKS AND MICRONUCLEUS FREQUENCY
|
| Guven M., Guven G.S., Oz E., Ozaydin A., Batar B., Ulutin T., Domanic N. |
| |
|
DNR ANALYSIS RESULTS IN THROMBOSES PATIENTS: THE FIRST DATA IN LATVIA
|
| Lejniece S., Lejnieks A., Steinbergs J., Vasiljeva I., Boka V., Udre I. |
| |
|
DO B:b INTERACTIONS HAVE A ROLE IN FIBRIN POLYMERIZATION?
|
| Litvinov R.I., Gorkun O.V., Galanakis D.K., Bowley S.R., Kostelansky M.S., Lord S.T., Weisel J.W. |
| |
|
DO HIGH SENSITIVITY C-REACTIVE PROTEIN AND CYSTATIN-C SERUM LEVELS PREDICT TOTAL MORTALITY IN HEART FAILURE PATIENTS?
|
| Gori A.M., Ognibene A., Marcucci R., Lenti M., Caldini A., Del Pace S., Nozzoli C., Verdiani V., Abbate R., Gensini G.F. |
| |
|
DO PATIENTS WITH HEPARIN INDUCED THROMBOCYTOPENIA HAVE ANTIBODIES TO ADAMTS-13
|
| Davidson S.J., Swain M. |
| |
|
DO POINT OF CARE DEVICES IMPROVE OUTCOMES IN PATIENTS ON ORAL ANTICOAGULANT THERAPY
|
| Wells P.S., Brown A., Jaffey J., Poon M. |
| |
|
DO WE COMPLETELY UNDERSTAND THE ANTITHROMBOTIC EFFECT OF ASPIRIN?
|
| Gurbel P.A., Bliden K.P., DiChiara J., Gesheff T.B., Javillo J., Tantry U.S. |
| |
|
DO WE NEED DIFFERENT STANDARD CURVES FOR MEASURING DIFFERENT LOW MOLECULAR WEIGHT HEPARINS?
|
| Chan A.K.C., Black L., Ing C., Williams S., Brandao L. |
| |
|
DOES ADMINISTRATION OF LANSOPRAZOLE AFFECT ASA ANTIPLATELET FUNCTION IN HIGH RISK CARDIOVASCULAR PATIENTS? PRELIMINARY RESULTS
|
| Anastasopoulou I., Laiou E., Sakizlis G., Tsoucala C., Gavalaki M., Adamopoulos A., Stergiou G., Markakis K., Karafoulidou A. |
| |
|
DOES ANGIOTENSIN II HAVE PROINFLAMMATORY OR PROTHROMBOTIC EFFECTS?
|
| Wallen H., Ekholm M., Kahan T., Broijersen A., Jorneskog G. |
| |
|
DOES DIFFERENT D-DIMER LEVEL REDUCE THE USE OF VENOUS DUPLEX SCANNING TO RULE OUT DEEP VEIN THROMBOSIS IN PATIENTS WITH SYMPTOMATIC PULMONARY EMBOLISM?
|
| Yamaki T., Nozaki M., Sakurai H., Takeuchi M., Soejima K., Kono T. |
| |
|
DOES INCREASING THE STARTING DOSE OF ENOXAPARIN RESULT IN BETTER TREATMENT OF CHILDREN REQUIRING THROMBOPROPHYLAXIS? A RETROSPECTIVE COHORT STUDY
|
| Belletrutti M., Bauman M., Mitchell L., Massicotte P. |
| |
|
DOES TESTING FOR ANTI BETA-2 GLYCOPROTEIN 1 ANTIBODIES ALTER CLINICAL PRACTICE IN PATIENTS WITH THE ANTIPHOSPHOLIPID SYNDROME?
|
| Patnaik M.M., Killeen A.A., Reding M.T., Kasthuri R.S. |
| |
|
DOES THE PRESENCE OF MULTIPLE INHERITED THROMBOPHILIC DEFECTS EXPLAIN THE INCREASED RISK OF ARTERIAL THROMBOTIC EVENTS IN PATIENTS WITH PRIOR VENOUS THROMBOEMBOLISM?
|
| Roshani S., Lijfering W.M., Coppens M., Hamulyák K., van der Meer J., Prins M.H., Büller H.R., Middeldorp S. |
| |
|
DOES THROMBIN GENERATION OR D-DIMER VALUES AT TIME OF AN ACUTE EVENT OF VENOUS THROMBO-EMBOLISM PREDICT RECURRENCES?
|
| Chaireti R.I., Jennersjö C., Lindahl T.L. |
| |
|
DOES TRANEXAMIC ACID DECREASE ERYTHROCYTE TRANSFUSION IN PATIENTS UNDERGOING HIP FRACTURE SURGERY WITH FONDAPARINUX FOR PREVENTION OF VENOUS THROMBOEMBOLISM ?
|
| Zufferey P.J., Miquet M., Quenet S., Laporte S., Martin P., Chambefort V., Molliex S., Mismetti P. |
| |
|
DOMAIN 5 PEPTIDES OF HIGH MOLECULAR MASS KININOGEN UNDERGO CONFORMATIONAL CHANGES INDUCED BY ZINC
|
| Pixley R., Bradford H., Isordia-Salas I., Roder H., Colman R.W. |
| |
|
DOPAMINE IS A COACTIVATOR FOR PLATELET ADHESION TO COLLAGEN AND ACTS VIA D2-LIKE RECEPTORS
|
| Schedel A., Schloss P., Klüter H., Bugert P. |
| |
|
DOSING EFFICACY AND SAFETY OF UNFRACTIONATED HEPARIN IN INFANTS WITH THROMBOTIC COMPLICATIONS
|
| Finkelstein T.S., Williams S., Ali M., Finkelstein Y., Kahr W.H., Chan A.K., Brandao L.R. |
| |
|
DOSING LEPIRUDIN IN PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA AND VARIOUS DEGREES OF RENAL FUNCTION IMPAIRMENT
|
| Tschudi M., Lämmle B., Alberio L. |
| |
|
DOUBLE MUTATION, A 2-BP DELETION AND VAL 211ILE, IN THE BLOOD COAGULATION FACTOR IX GENE IN A PATIENT WITH SEVERE HEMOPHILIA B
|
| Seita I., Shinozawa K., Kato H., Koh A., Tsujikawa A., Suzuki T., Amano K., Inaba H., Fukutake K. |
| |
|
DOUBLE STRANDED RNA-MEDIATED MODULATION OF THE BALANCE BETWEEN TISSUE FACTOR AND THROMBOMODULIN ON THE ENDOTHELIUM: RELEVANCE FOR DYSFUNCTIONAL HAEMOSTASIS IN VIRAL INFECTIONS
|
| Shibamiya A., Hersemeyer K., Daniel J.M., Schmidt-Woell T., Koyama T., Bauer S., Sedding D.G., Preissner K.T., Kanse S.M. |
| |
|
DOUBLE-DEFICIENCY OF RAC1 AND CDC42 SEVERELY AFFECTS PLATELET PRODUCTION AND FUNCTION
|
| Pleines I., Elvers M., Wu X., Chrostek A., Strehl A., Brakebusch C., Nieswandt B. |
| |
|
DOWN REGULATION OF THROMBOTIC AND INFLAMMATORY MEDIATORS IN PATIENTS WITH ACUTE CORONARY SYNDROME TREATED WITH CLOPIDOGREL. RELEVANCE TO THE OBSERVED CLINICAL EFFECTS
|
| Fareed D., Bick R., Hoppensteadt D., Jeske W.P., Lewis B.E., Walenga J.M., Fareed J. |
| |
|
DOWN-REGULATION OF ACTIVATED FACTOR XIII BY POLYMORPHONUCLEAR GRANULOCYTE PROTEASES WITHIN THE FIBRIN CLOT
|
| Bagoly Z., Haramura G., Muszbek L. |
| |
|
DRUG ELUTING STENTS: RESTENOSIS VERSUS THROMBOSIS ?
|
| van Belle E., Susen S., Jude B., Bertrand M.E. |
| |
|
DUAL ANTIPLATELET THERAPY WITH CLOPIDOGREL AND ASPIRIN ATTENUATES PLATELET REACTIVITY AND PROTHROMBOTIC EFFECT OF ERYTHROCYTES IN PATIENTS AFTER CAROTID STENTING
|
| Valles J., Lago A., Tembl J., Moscardo A., Fuset M., Breña S., Santos M.T. |
| |
|
DUAL EFFECT OF PLATELET-DERIVED MATRIX METALLOPROTEINASES ON OCCLUSIVE THROMBUS GROWTH
|
| Cosemans J.M.E.M., van der Meijden P.E.J., Cleutjens J.P.M., Heeneman S., Heemskerk J.W.M. |
| |
|
DUAL GENE TRANSFER OF FGF-2 AND PDGF-BB USING PLASMID DNA PROMOTES EFFECTIVE ANGIOGENESIS AND ARTERIOGENESIS IN A RODENT MODEL OF HINDLIMB ISCHEMIA
|
| De Paula E.V., Flores-Nascimento M.C., Garcia R.A., Ramos C.D., Guillaumon A.T., Arruda V.R., Annichino-Bizzacchi J.M. |
| |
|
DURATION OF SYMPTOMS AND D-DIMER TESTING FOR VENOUS THROMBOEMBOLISM RULING-OUT
|
| de Bastos M., de Bastos M.R.D., Bogutchi T., Carneiro-Proietti A.B.F., Rezende S.M. |
| |
|
DYNAMIC SIGNALLING EVENTS AND FIBRIN-INDEPENDENT RETRACTION CONTRIBUTE TO THROMBUS STABILITY UNDER SHEAR
|
| Auger J.M., Watson S.P. |
| |
|
DYNAMICS OF DISINTEGRIN DISRUPTION OF INTEGRIN STRUCTURE AND FUNCTION
|
| Hantgan R.R., Stahle M.C., Connor J.H., Connor R.F., Mousa S.A., McLane M.A., Buchmueller K.L., Weisel J.W., Horita D.A., Rocco M. |
| |
|
DYSFUNCTION ENDOTHELIAL AND ANGIOGENIC ACTIVITY IN CHRONIC HEART FAILURE: ROLE OF ORAL ANTICOAGULANT THERAPY
|
| Vila V., Martínez Sales V., Almenar L., Sánchez Lázaro I., Villa P., Reganon E. |
| |
|
DYSREGULATION OF ALTERNATIVE SPLICING OF COAGULATION FACTOR V RESULTS IN BLEEDING DISORDER, EAST TEXAS TYPE (OMIM 605913)
|
| Vincent L.M., Tran S., Tran-Fadulu V., Dubinsky W.P., Dahlback B., Milewicz D.M. |
| |
